¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Remote Patient Monitoring Software And Services Market Size, Share & Trends Analysis Report By Type, By Application, By End-user, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1405021
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,191,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,568,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,321,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 650¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2024³âºÎÅÍ 2030³â±îÁö ¿¹Ãø ±â°£ µ¿¾È ÀÌ ½ÃÀåÀº 34.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º´Â ÀÇ·á Àü¹®°¡°¡ ¿ø°ÝÀ¸·Î ȯÀÚÀÇ Áúº´ ÁøÇàÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀ» ÅëÇØ ÀÓ»óÀǴ ȯÀÚÀÇ »óÅ¿¡ µû¶ó Ä¡·á °èȹ°ú ÀÚ°¡ ±³À°À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°è °¢±¹ Á¤ºÎÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ÀÇ 1Àδç ÀÇ·áºñ ÁöÃâÀº 2019³â 10,921´Þ·¯¿¡¼­ 2021³â 12,318´Þ·¯·Î Áõ°¡Çß½À´Ï´Ù. ÀÌ´Â ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ Àý°¨¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î´Â º´¿ø ¹æ¹® Ƚ¼ö¸¦ ÁÙÀÌ´Â µ¿½Ã¿¡ Áúº´ °¨¿° À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ¾î ȯÀÚµéÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÇ»çµé »çÀÌ¿¡¼­ RPM ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ÀÇ»çÇùȸÀÇ Á¶»ç¿¡ µû¸£¸é ÃÖ±Ù ¸î ³âµ¿¾È RPM ÀåºñÀÇ Ã¤ÅÃÀÌ Å©°Ô Áõ°¡Çß´Ù°í ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º¸¦ »ç¿ëÇÏ´Â ÀÇ»ç´Â 2016³â 12%¿¡¼­ 2022³â 30%·Î Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó ÀÇ»ç°áÁ¤ Áö¿øÀ» À§ÇØ µðÁöÅÐ Çコ ÅøÀ» »ç¿ëÇÏ´Â ÀÇ»çÀÇ ¼ö´Â 2016³â 28%¿¡¼­ 2022³â 47%±îÁö Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ÀÌ´Â ¼­ºñ½º µµÀÔÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼­ºñ½º¿¡ ´ëÇÑ º¸Çè Àû¿ë ±¹°¡ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, PrevounceÀÇ ±â»ç¿¡ µû¸£¸é, 2021³â 4¿ù ÇöÀç ¹Ì±¹ ³» 26°³ ÁÖ¿¡¼­ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¸ÞµðÄÉÀ̵å Àû¿ëÀ» ½ÂÀÎÇß½À´Ï´Ù. ¶ÇÇÑ ÀÌ ±â»ç¿¡ µû¸£¸é, ÇÑ ´Þ¿¡ 20ºÐÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀ» Á¦°øÇÏ¸é ¸ÞµðÄÉ¾î ¼öÇýÀÚ´Â 12°³¿ù µ¿¾È ¾à 1,400´Þ·¯ÀÇ º¸»óÀ» ¹ÞÀ» ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù.

¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

  • 2023³â¿¡´Â ¼­ºñ½º ºÎ¹®ÀÌ 78.2%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÇ·á ½Ã¼³ÀÇ ºÎ´ãÀ» ÁÙÀ̱â À§ÇØ º´¿ø°ú ÀÇ»çÀÇ RPM ¼­ºñ½º äÅÃÀÌ Áõ°¡Çϸ鼭 ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù.
  • 2023³â¿¡´Â ¾ËÃ÷ÇÏÀ̸Ӻ´, °íÇ÷¾Ð, ¸¶ºñ, °üÀý¿° µî ±âŸ ¸¸¼º ÁúȯÀ» Æ÷ÇÔÇÑ ±âŸ ÀÀ¿ë ºÐ¾ß°¡ 53.5%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ RPM ¼­ºñ½ºÀÇ ³ôÀº äÅ÷ü µîÀÌ ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
  • 2023³â¿¡´Â °ø±ÞÀÚ ºÎ¹®ÀÌ 44.0%·Î °¡Àå Å« ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ¿ø°Ý ȯÀÚ Ä¡·á¸¦ Á¦°øÇÏ´Â RPM ¼ÒÇÁÆ®¿þ¾îÀÇ Ã¤Åà Áõ°¡ µîÀÌ ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù.
  • 2023³â¿¡´Â ºÏ¹Ì°¡ 51.2%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç¿Í RPM ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º äÅÃÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ È£ÀÇÀûÀÎ ³ë·Â ´öºÐÀÔ´Ï´Ù.

    ¸ñÂ÷

    Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

    Á¦2Àå ÁÖ¿ä ¿ä¾à

    Á¦3Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

    • º¸±Þ ¹× ¼ºÀå Àü¸Á ¸ÅÇÎ
    • ½ÃÀå ¿ªÇÐ
      • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå ºÐ¼® Åø
      • ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
      • PESTEL ºÐ¼®
      • ÁÖ¿ä °Å·¡¿Í Àü·«Àû Á¦ÈÞ ºÐ¼®
      • ½ÅÇü Äڷγª¹ÙÀÌ·¯½º(COVID-19) ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

    Á¦4Àå Á¦5Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

    • Á¤ÀÇ¿Í ¹üÀ§
    • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
    • ¼ÒÇÁÆ®¿þ¾î
    • ¼­ºñ½º

    Á¦5Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

    • Á¤ÀÇ¿Í ¹üÀ§
    • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
    • ¾Ï
    • ½ÉÇ÷°üÁúȯ
    • ´ç´¢º´
    • ¼ö¸éÀå¾Ö
    • ±âŸ

    Á¦6Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚ ÃßÁ¤¡¤µ¿Ç⠺м®

    • Á¤ÀÇ¿Í ¹üÀ§
    • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚ º¯µ¿ ºÐ¼®
    • ÁöºÒÀÚ
    • ȯÀÚ
    • Á¦°øÀÚ

    Á¦7Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

    • Áö¿ª ½ÃÀå ½º³À¼ô
    • ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå : Áö¿ª º¯µ¿ ºÐ¼®
    • ºÏ¹Ì
      • À¯Çüº°(2018-2030³â)
      • ¿ëµµº° 2018³â-2030³â
      • ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
      • ¹Ì±¹
      • ij³ª´Ù
    • À¯·´
      • À¯Çüº°(2018-2030³â)
      • ¿ëµµº° 2018³â-2030³â
      • ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ·¯½Ã¾Æ
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • À¯Çüº°(2018-2030³â)
      • ¿ëµµº° 2018³â-2030³â
      • ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
      • ÀϺ»
      • Áß±¹
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ½Ì°¡Æ÷¸£
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • À¯Çüº°(2018-2030³â)
      • ¿ëµµº° 2018³â-2030³â
      • ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ¾Æ¸£ÇîÆ¼³ª
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • À¯Çüº°(2018-2030³â)
      • ¿ëµµº° 2018³â-2030³â
      • ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

    Á¦8Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå - °æÀï ±¸µµ

    • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
    • °æÀï ºÐ·ù
    • º¥´õ ±¸µµ
      • °ø°³ ȸ»ç
      • ºñ°ø°³ ȸ»ç

    Á¦9Àå ±â¾÷ °³¿ä

    • Teladoc Health, Inc
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • Medtronic Plc.
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • GE Healthcare
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • Siemens Healthineers AG
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • Philips Healthcare
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • Caretaker Medical
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • OMRON Healthcare
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    • BioIntelliSense
      • ±â¾÷ °³¿ä
      • À繫 ½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å·
      • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
    LSH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    Remote Patient Monitoring Software And Services Market Growth & Trends:

    The global remote patient monitoring software and services market size is expected to reach USD 65.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 34.9 % during the forecast period from 2024 to 2030. Remote patient monitoring (RPM) software and services help healthcare professionals monitor disease progression in patients remotely. These solutions also allow clinicians to provide care plans and self-education to patients based on their conditions.

    Rising healthcare spending by governments across the globe is a major driver for market growth. For instance, the U.S. per capita healthcare spending increased from USD 10,921 in 2019 to USD 12,318 in 2021. This is anticipated to further boost the growth. Moreover, rising demand to curb healthcare costs is anticipated to drive growth. Remote patient monitoring software helps reduce hospital visits while also reducing the risk of disease transmission, which is anticipated to increase its adoption by patients.

    Increasing adoption of RPM solutions among physicians is expected to be a key market growth driver. For instance, according to an American Medical Association survey, the adoption of RPM devices has witnessed tremendous growth in recent years. Physicians using these software and services increased from 12% in 2016 to 30% in 2022. The article also states that the number of physicians using digital health tools for clinical decision support has increased from 28% in 2016 to 47% in 2022. This is expected to boost the adoption of services. The rising number of countries providing coverage for remote patient monitoring services is anticipated to drive the market's growth. For instance, according to an article by Prevounce, as of April 2021, 26 states in the U.S. approved Medicaid coverage for remote patient monitoring. The article also states that by providing 20 minutes of remote patient monitoring a month, a Medicare receiver can get compensation of about USD 1,400 for 12 months.

    Remote Patient Monitoring Software And Services Market Report Highlights:

    Table of Contents

    Chapter 1. Methodology and Scope

    Chapter 2. Executive Summary

    Chapter 3. Remote Patient Monitoring Software and Services Market Variables, Trends, & Scope

    Chapter 4. Chapter 5 Remote Patient Monitoring Software and Services Market: Type Estimates & Trend Analysis

    Chapter 5. Remote Patient Monitoring Software and Services Market: Application Estimates & Trend Analysis

    Chapter 6. Remote Patient Monitoring Software and Services Market: End-user Estimates & Trend Analysis

    Chapter 7. Remote Patient Monitoring Software and Services Market: Regional Estimates & Trend Analysis

    Chapter 8. Remote Patient Monitoring Software and Services Market - Competitive Landscape

    Chapter 9. Company Profiles

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â